AI Consensus Investment Thesis
Intuitive Surgical (ISRG) Stock Forecast and AI Rating
Forecast targets and rating
Final recommendation
BUY
Calculated from the frozen synthesized path using the same return, horizon, volatility and dividend rules as individual opinions.
1-Year
NEUTRAL$432
+9.7%5-Year
BUY$663
+68.6%Latest flagship insight
Robotic Surgical Monopoly Confronts Hospital Capital Rationing And Margin Concessions
There is high consensus that non-discretionary surgical procedure volumes and recurring consumable sales insulate cash generation from macroeconomic volatility. However, sharp divergence exists regarding valuation durability, as elevated interest rates, operating-lease mix shifts, and arriving multiport competition threaten long-term profit margins.
This is the latest published deep-analysis batch. Audit published forecasts in full transparency
Ray Dalio (Strategist), Machiavelli (Insider), Universal Investor (Polymath), Warren Buffett (Value Purist), Superintelligence (Anthropologist), Sherlock Holmes (Whistleblower), Elon Musk (Visionary), Michael Burry (Vulture), J.P. Morgan (Titan). Some archetypes run in multiple modes, resulting in 14 advisors total.
Gemini
Claude
ChatGPTExecutive Summary
Dotted terms open concise definitions. Browse technical terms
If you invested $10,000 in Intuitive Surgical at the forecast anchor (2026-09-18): $16,857 in five years versus $13,892 for S&P 500 benchmark.
20-quarter synthesized forecastPrice targets, quarterly returns and the reasoning behind each stepView tableClose table
Frozen forecast from 18 Sept 2026. Prices in USD; returns exclude dividends. Each quarter is compounded from the previous quarter.
Swipe the table horizontally to read every column.
| Quarter | Target (USD) | Quarter return | Total return | Forecast rationale |
|---|---|---|---|---|
| Q4 2026 | 399.38 | +1.54% | +1.54% | Year-end procedure volume resilience and initial da Vinci 5 commercial shipments counter restrictive monetary policy headwinds, allowing high-margin instrument turnover to support modest valuation stabilization. |
| Q1 2027 | 407.03 | +1.92% | +3.48% | Fiscal 2027 guidance introduces conservative revenue-per-procedure assumptions from the extended-use instrument rollout and hospital capex freezes, prompting estimate recalibration and mild multiple compression. |
| Q2 2027 | 421.20 | +3.48% | +7.09% | First-quarter procedure data confirms that underlying surgical volume growth remains durable above fourteen percent, while European regulatory momentum cushions domestic capital equipment procurement delays. |
| Q3 2027 | 431.58 | +2.46% | +9.72% | Summer surgical seasonality moderates procedural turnover, but progressive adoption of force-feedback instrumentation and steady share repurchases maintain predictable per-share cash-flow compounding. |
| Q4 2027 | 449.64 | +4.19% | +14.32% | Hospital fiscal year-end budget flushes drive a seasonal inflection in multiport replacements, lifting fourth-quarter console shipments and validating operating margin resilience above thirty percent. |
| Q1 2028 | 457.84 | +1.82% | +16.40% | Rival commercial launches introduce competitive tender friction and pricing scrutiny, yet surgeon switching inertia and established clinical workflows prevent meaningful customer defection. |
| Q2 2028 | 469.50 | +2.55% | +19.36% | Manufacturing scale on fifth-generation components reduces unit costs, absorbing instrument pricing concessions and driving healthy operating cash-flow conversion across expanded clinical indications. |
| Q3 2028 | 483.15 | +2.91% | +22.84% | Recurring consumable replenishment across academic and community hospitals buffers seasonal procedure moderation, preserving solid free cash flow generation despite persistent high borrowing benchmarks. |
| Q4 2028 | 501.85 | +3.87% | +27.59% | Year-end fleet upgrades accelerate as hospital networks standardize on advanced computational consoles, propelling annual operating cash flow and funding continued programmatic equity retirements. |
| Q1 2029 | 515.37 | +2.69% | +31.03% | First-quarter procedural volumes maintain steady low-teens expansion, led by general surgery and thoracic indications, while leasing collections provide highly visible recurring cash streams. |
| Q2 2029 | 531.02 | +3.04% | +35.01% | Early commercialization of digital surgical analytics and simulation subscriptions begins adding high-margin recurring software revenue, supporting steady incremental operating margin expansion. |
| Q3 2029 | 544.64 | +2.56% | +38.47% | International procedure expansion across Europe and developed Asia compensates for domestic market maturation, maintaining overall revenue momentum despite competitive pressure in secondary markets. |
| Q4 2029 | 564.01 | +3.56% | +43.39% | Robust fourth-quarter capital installations and record consumable shipments drive strong annual cash conversion, cementing the platform's role as an indispensable surgical utility. |
| Q1 2030 | 575.08 | +1.96% | +46.21% | Demographic aging continues to expand non-discretionary oncology and pelvic floor caseloads, providing a predictable procedural floor that shields earnings from broader late-cycle macroeconomic deceleration. |
| Q2 2030 | 586.68 | +2.02% | +49.16% | Expanded regulatory clearances for outpatient ambulatory surgery center applications broaden the accessible procedure pool, sustaining healthy instrument pull-through per installed console. |
| Q3 2030 | 601.46 | +2.52% | +52.91% | Installed base scale exceeding fourteen thousand systems generates an unshakeable consumable toll, neutralizing seasonal elective procedure dips and preserving fortress balance sheet liquidity. |
| Q4 2030 | 619.67 | +3.03% | +57.54% | Solid fiscal year-end console placements and expanding software integration generate superior cash conversion, enabling management to execute steady accretive share repurchases. |
| Q1 2031 | 631.55 | +1.92% | +60.56% | Normalized low-teens procedural growth establishes a mature compounding cadence, where earnings expansion drives equity appreciation while terminal valuation multiples settle near historical medtech averages. |
| Q2 2031 | 648.68 | +2.71% | +64.92% | Advanced endoscopic platforms and single-port applications deepen hospital workflow entrenchment, generating steady high-margin consumable turnover across diverse surgical specialties. |
| Q3 2031 | 663.04 | +2.21% | +68.57% | The forecast period concludes with undisputed robotic ecosystem leadership, where massive procedural cash generation and pristine balance-sheet strength cement durable through-cycle shareholder returns. |
The base-case investment thesis balances secular surgical robotics adoption against structural multiple compressionmultiple compressionA decline in valuation ratios such as price-to-earnings or enterprise-value-to-sales.View full glossary entry in a restrictive interest-rate regime. Intuitive Surgical's economic engine is anchored by an installed baseinstalled baseThe active set of deployed products or users already in operation with existing customers.View full glossary entry exceeding 11,700 systems, generating over 80% recurring revenuerecurring revenueRevenue expected to repeat under subscriptions, contracts, renewals, or recurring customer usage.View full glossary entry through proprietary instruments, accessories, and service contracts. This razor-and-blade model decouples cash generation from lumpy hospital capital expenditurecapital expenditureCapital expenditure (CAPEX) is spending on long-lived assets or major improvements expected to support operations over multiple periods.View full glossary entry cycles. However, valuation sensitivity remains acute. At 45x trailing earnings, the equity functions as a long-duration asset vulnerable to discount-rate pressure and hospital capital rationing. Furthermore, self-inflicted price concessions via the 2027 Extended Use Program, alongside the arrival of cleared competitors, will decouple revenue growth from procedure volume.
Key insights
- Operating lease migration preserves installed-base placement velocity but lengthens cash payback periods and dilutes upfront revenue recognitionrevenue recognitionRevenue recognition is the accounting process for recording sales when performance obligations are satisfied and economic benefits are reasonably measurable.View full glossary entry across hospital networks.
- Extended-use instrument programs pre-emptively defend market share against emerging modular competitors but cap medium-term consolidated gross margin expansiongross margin expansionAn increase in gross profit as a percentage of revenue.View full glossary entry below 68%.
- Free cash flow conversionfree cash flow conversionThe proportion of earnings, EBITDA, or another operating measure converted into free cash flow over a specified period.View full glossary entry exceeding 100% of net income funds continuous share repurchases, transforming operational compounding into per-share equity accretion.
Intuitive Surgical makes the robotic systems and specialized tools used in minimally invasive surgeries worldwide. While hospitals are currently cautious about buying expensive multimillion-dollar equipment due to high interest rates, actual patient surgeries continue growing at a steady double-digit pace. Because Intuitive generates over 80% of its revenue from selling single-use instruments and service contracts for each operation, its cash flow remains highly reliable. Investors must balance this steady operational growth against a premium stock price and arriving commercial competition.
Key insights
- Routine patient surgeries continue expanding regardless of economic conditions, ensuring dependable day-to-day instrument sales.
- Hospitals increasingly choose to lease systems rather than buying outright, stretching cash collections over longer periods.
- Programs lowering instrument costs help protect customer loyalty against new competitors but limit near-term profit growth.
Deep Dive
Prevailing market consensus views Intuitive Surgical as an elite medtech compoundercompounderA business or asset that can reinvest earnings or cash flows at attractive returns over an extended period.View full glossary entry whose da Vinci 5 rollout ensures uninterrupted mid-teens procedural compounding. Investors treat the razor-and-blade consumable model as largely impervious to broader economic headwinds. However, media commentary and sell-side price target reductions reflect growing anxiety that elevated sovereign bond yields, post-pandemic procedure normalization, and arriving soft-tissue competition from multinational healthcare conglomerates will permanently cap valuation multiples.
Paywalled preview begins: Deep Dive: detailed analysis
From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.
Deep Dive
Alpha Gap & Repricing Catalysts
Where does the current market narrative diverge from our AI Opinions—and what could close the gap?
Market Narrative
What does the market currently expect? Prevailing market consensus views Intuitive Surgical as an elite medtech compoundercompounderA business or asset that can reinvest earnings or cash flows at attractive returns over an extended period.View full glossary entry whose da Vinci 5 rollout ensures uninterrupted mid-teens procedural compounding. Investors treat the razor-and-blade consumable model as largely impervious to broader economic headwinds. However, media commentary and sell-side price target reductions reflect growing anxiety that elevated sovereign bond yields, post-pandemic procedure normalization, and arriving soft-tissue competition from multinational healthcare conglomerates will permanently cap valuation multiples.
Alpha Gap
What is the biggest difference between market expectations and our AI forecasts? The crowd modestly underestimates Intuitive's valuation durability, but overestimates the near-term velocity of outright hardware capital sales. The market fixates on quarterly console delivery optics, overlooking that recurring instruments and services generate over 80% of turnover. However, consensus models also ignore the 2027 Extended Use Program, which voluntarily surrenders instrument pricing per procedure to lock out competitors. This creates a nuanced alpha gapalpha gapA difference between an investment view of potential excess return and the excess return implied by current market expectations.View full glossary entry: operational compounding is more resilient than feared, but gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry face a structural ceiling.
Repricing Catalyst
What could make the market recognize and close that gap? Upcoming financial reporting through fiscal 2027 will resolve the gap between headline capital equipment concerns and procedural cash durability. The critical trigger will be reported gross margingross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry stability near 68% and sustained mid-teens recurring consumable revenue expansion as da Vinci 5 utilization deepens. Confirmation that instrument pull-through outpaces hardware placement lumpiness will compel institutional asset allocators to reprice the shares based on resilient through-cycle cash flows.
Sentiment and Timing
What do sentiment, volatility, and the market-recognition cycle suggest about the thesis timing?
- Greed / Fear
- Fear
- Volatility
- Moderate
- Cycle position
- Stabilization
Sentiment exhibits fear driven by multiple compressionmultiple compressionA decline in valuation ratios such as price-to-earnings or enterprise-value-to-sales.View full glossary entry and healthcare capexcapital expenditureCapital expenditure (CAPEX) is spending on long-lived assets or major improvements expected to support operations over multiple periods.View full glossary entry tightening, yet volatility expectations remain moderate. The primary disagreement centers on whether the stock is stabilizing into a mature compoundercompounderA business or asset that can reinvest earnings or cash flows at attractive returns over an extended period.View full glossary entry or risking further multiple de-rating as competitors enter.
Macro Regime Fit
Does the current market environment support the thesis? The prevailing monetary regimemonetary regimeThe prevailing framework of central-bank policy, interest rates, money creation, and exchange-rate management.View full glossary entry of elevated policy rates and restrictive sovereign yields presents a clear headwind for hospital debt financing and equity duration multiples. However, surgical procedure demand exhibits near-zero elasticity to macroeconomic cycles. Intuitive's zero-debt fortress balance sheetfortress balance sheetA financial position with high liquidity and low debt, providing resilience against market volatility.View full glossary entry, substantial net cash reserves, and self-funded capital deployment insulate operations, transforming external credit constraints into a relative competitive moateconomic moatCompetitive advantage protecting market share and profitability from rivals.View full glossary entry against levered medtech rivals.
Advisor Disagreement
What do our AI Advisors disagree about most? The primary debate across reports concerns terminal valuationterminal valuationTerminal valuation is the estimated value of an asset or business beyond the explicit forecast period in a discounted cash flow model.View full glossary entry multiples and the durability of pricing powerpricing powerThe ability of a company to raise prices without losing significant customer demand.View full glossary entry. Bullish analyses assume that procedural compounding and surgeon residency lock-in will preserve a premium multiple above 40x earnings, arguing that competitor platforms will remain irrelevant. Conversely, cautious perspectives emphasize that 5% bond yields fundamentally re-rate growth equities, while the commercial arrival of Medtronic's Hugo and J&J's Ottava arms hospital procurement committees with bargaining leverage. Furthermore, reports disagree on whether the 2027 Extended Use Program represents a margin-diluting price concession or an unassailable defensive moat that accelerates customer volume.
Base-Case Forces
Event Risk ScoreLow34/100Near-certain positive forces
Top Drivers / Tailwinds
Near-certain forces that support the investment thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Driver / Tailwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Recurring Consumables Tollbooth Compounding | Competitive Positioning | +28% | +35% | Proprietary instruments, specialized accessories, and multi-year service contracts generate over 80% of total revenue. As worldwide surgical procedures expand at 14% to 16% annually across general surgery, thoracic, and colorectal indications, recurring consumable turnover compounds automatically. This procedure-linked tollbooth shields cash generation from hospital capital expenditurecapital expenditureCapital expenditure (CAPEX) is spending on long-lived assets or major improvements expected to support operations over multiple periods.View full glossary entry freezes, ensuring predictable double-digit operational cash flows across macroeconomic cycles. |
| Fifth-Generation Platform Upgrade Supercycle | Innovation And Product | +24% | +26% | The commercial deployment of da Vinci 5 drives a multi-year hardware replacement cycle across an installed baseinstalled baseThe active set of deployed products or users already in operation with existing customers.View full glossary entry exceeding 11,700 systems. Featuring force-feedback sensing, tenfold computational processing capability, and 11% higher procedural throughput, the console compels health networks to upgrade aging fleets. This platform refresh commands premium average selling prices and locks in multi-year service contracts. |
| Global Demographic Minimally Invasive Migration | Sector And Industry | +18% | +20% | Aging populations across North America, Europe, and developed Asia structurally drive incidence curves in oncological, urological, and soft-tissue pathologies. Concurrently, hospital administrators prioritize robotic minimally invasive interventions to shorten inpatient hospital stays and lower surgical complication rates. This clinical necessity expands procedure volumes and drives geographic penetration across under-indexed international healthcare delivery systems. |
| Fortress Balance Sheetfortress balance sheetA financial position with high liquidity and low debt, providing resilience against market volatility.View full glossary entry Self-Funded Buybacks | Capital Allocation | +14% | +15% | Intuitive generates trailing free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry exceeding $3.2 billion with zero gross debt and over $8.6 billion in liquid reserves. Having completed major manufacturing facility expansions, capital expenditurecapital expenditureCapital expenditure (CAPEX) is spending on long-lived assets or major improvements expected to support operations over multiple periods.View full glossary entry intensity has normalized near 5% of revenue. Management redeploys surplus cash into programmatic share repurchases, systematically retiring equity floatfloatThe number of shares available for public trading in the market.View full glossary entry and accreting per-share earnings without relying on debt markets. |
Near-certain negative forces
Top Frictions / Headwinds
Near-certain forces that could slow, cap, or damage the thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Friction / Headwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Restrictive Cost of Capitalcost of capitalCost of capital is the required return investors demand to fund a business, project, or asset, reflecting risk and financing mix.View full glossary entry Compression | Macroeconomic And Macrofinancial | -17% | -4.0% | Sovereign bond yields near 5.0% and central bank policy rates around 4.0% impose persistent discount-rate gravity on long-duration healthcare growth equities. Intuitive's trailing price-to-earnings multipleearnings multipleThe ratio of share price to earnings per share used to determine stock valuation.View full glossary entry of 45x faces structural resistance against returning to historical peak multiples. This macroeconomic constraint forces shareholder returns to track underlying operational earnings compounding rather than multiple re-expansion. |
| Hospital Capital Freezes and Leasing Shift | Macroeconomic And Macrofinancial | -13% | -11% | Healthcare systems facing labor cost inflation and tight operating marginsoperating marginsOperating profit as a percentage of revenue after operating expenses, before interest and taxes.View full glossary entry are increasingly deferring outright multimillion-dollar console purchases. Instead, hospitals demand operating leases and usage-based financing. While leasing preserves long-term placement volume, it defers upfront hardware revenue recognitionrevenue recognitionRevenue recognition is the accounting process for recording sales when performance obligations are satisfied and economic benefits are reasonably measurable.View full glossary entry, increases Intuitive's balance-sheet asset commitments, and modestly dampens near-term return on invested capitalreturn on invested capitalReturn on invested capital (ROIC) measures how efficiently a business generates after-tax operating profit from the capital invested in its operations.View full glossary entry. |
| Cleared Multiport Competitor Tender Encroachment | Competitive Positioning | -11% | -10% | Regulatory clearances for Medtronic's Hugo and Johnson & Johnson's Ottava platforms formally end Intuitive's absolute domestic monopoly in soft-tissue robotics. While clinical switching barriers and surgeon training remain formidable moats, hospital procurement committees exploit competing platforms to demand instrument bundle discounts and favorable trade-in terms, exerting downward pressure on hardware pricing. |
| Extended-Use Pricing and Procurement Concessions | Regulatory | -9.0% | -10% | The scheduled rollout of extended-use instruments in 2027 deliberately lowers customer cost-per-procedure in high-volume benign surgeries to deny rivals a market opening. However, this self-inflicted concession decouples instrument revenue growth from underlying procedure expansion. Combined with international volume-based procurement pressures, this dynamic establishes an observable near-term ceiling on gross margin expansiongross margin expansionAn increase in gross profit as a percentage of revenue.View full glossary entry. |
What Could Break or Accelerate the Thesis
Plausible downside scenarios
Tail Risks
Tail yet plausible downside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Federal Robotic Procedural Reimbursement Carve-Out | 22% | -28% | Mounting healthcare entitlement deficits could prompt CMS to enact restrictive bundled payments or site-neutral caps that eliminate premium reimbursement for robotic-assisted laparoscopic surgery by 2028. Lacking financial incentives in routine hernia or gallbladder repairs, hospitals would curtail robotic consumable utilization, reducing procedure growth to single digits and compressing gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry. |
| Catastrophic Systemic Sensor Recall Event | 14% | -34% | A critical defect in da Vinci 5's force-feedback sensor architecture or an algorithmic firmware flaw leading to intraoperative vascular complications could trigger a mandatory FDA Class I recall. Regulators would halt console shipments and suspend surgical procedures pending retrofits, inflicting massive remediation costs, litigation liabilities, and severe reputational damage. |
Plausible upside scenarios
Tail Opportunities
Tail yet plausible upside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Autonomous Surgical Guidance Regulatory Breakthrough | 28% | +32% | Regulators could grant breakthrough clearance by 2028 for real-time intraoperative AI surgical guidance and automated suturing sub-tasks on da Vinci 5. This would transform the console from a tele-manipulator into an active clinical assistant, unlocking recurring enterprise software subscriptions of over $150,000 annually per system and expanding gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry beyond 72%. |
| Universal Outpatient Ambulatory Surgical Penetration | 32% | +25% | A coordinated overhaul by CMS and commercial payers establishing enhanced, site-neutral procedural reimbursement parity by 2027 would accelerate robotic adoption in ambulatory surgery centers. Intuitive's compact single-port and da Vinci 5 variants would rapidly penetrate outpatient facilities, doubling addressable domestic surgical volume and expanding consumable sales beyond 22% annually. |
Company Financial Analysis
Intuitive Surgical Earnings and Financials Analysis by AI
Financial figures available as of Sep 20, 2026. Only filings and source records available by this analysis date are included.
Earnings and financials
AI Review
Intuitive's financial performance demonstrates an exceptional compounding engine driven by non-discretionary patient procedures. Trailing twelve-month revenue reached $11.03 billion by mid-2026, supported by robust 18.5% year-over-year growth in the second quarter. Net income advanced to $3.14 billion, propelled by double-digit procedure growth and expanding demand for the da Vinci 5 system. Crucially, recurring sales of single-use instruments, accessories, and maintenance contracts now represent over 80% of total turnover, insulating top-line performance from cyclical healthcare slowdowns. The real strength of this business lies in its remarkable cash generation. Trailing free cash flow reached $3.22 billion, converting net income into cash at a rate exceeding 100%. This highlights an essential procedural utility whose cash generation remains completely self-funding.
Revenue, earnings, and cash flow
The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.
| Fiscal year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | USD 10.1B | USD 2.9B | USD 2.5B |
| 2024 | USD 8.4B | USD 2.3B | USD 1.3B |
| 2023 | USD 7.1B | USD 1.8B | USD 749.6M |
| 2022 | USD 6.2B | USD 1.3B | USD 958.4M |
| 2021 | USD 5.7B | USD 1.7B | USD 1.7B |
Valuation context: historical P/E
The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.
| Fiscal year | P/E | Earnings basis | Currency basis | Ticker / reporting |
|---|---|---|---|---|
| 2025 | 71.5x | TTM | Native | USD / USD |
| 2024 | 81.8x | TTM | Native | USD / USD |
| 2023 | 67.2x | TTM | Native | USD / USD |
| 2022 | 71.6x | Annual | Native | USD / USD |
| 2021 | 77.4x | Annual | Native | USD / USD |
P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.
Profitability and margins
AI Review
Operating profitability exhibits structural resilience anchored by high-margin consumable instrument sales. Gross margin held stable at 66.0% in fiscal 2025, while operating margin expanded to 29.3%, reaching 31.3% on a trailing twelve-month basis by mid-2026. This operational leverage shows that steady procedural volume growth and administrative cost control easily absorbed early manufacturing startup expenses for the da Vinci 5 console. The underlying story is driven by a highly favorable product mix. Recurring instruments and services generate gross margins near 70%, offsetting the introductory overhead of building advanced robotic consoles. As manufacturing efficiencies for new sensors mature, fixed factory costs will spread across higher unit volumes, structurally protecting operating margins despite competitive market pressures.
The table compares up to five fiscal years of operating income and reported profitability margins.
| Fiscal year | Operating income | Operating margin | Net margin |
|---|---|---|---|
| 2025 | USD 2.9B | 29.3% | 28.4% |
| 2024 | USD 2.3B | 28.1% | 27.8% |
| 2023 | USD 1.8B | 24.8% | 25.2% |
| 2022 | USD 1.6B | 25.3% | 21.3% |
| 2021 | USD 1.8B | 31.9% | 29.9% |
Balance sheet and leverage
AI Review
Intuitive maintains a classic fortress balance sheet engineered for complete strategic independence. The company operates with zero long-term funded debt, carrying a debt-to-equity ratio of just 0.02 that reflects only standard operating leases. With total stockholders' equity of $17.82 billion, a current ratio of 4.87, and over $8.6 billion in cash and liquid investments, the business faces no debt refinancing risks in a high-interest-rate world. This liquidity buffer provides vital strategic flexibility. While financially strained hospital customers navigate higher borrowing benchmarks, Intuitive can comfortably offer flexible equipment leasing structures directly from its own reserves. Furthermore, management can opportunistically deploy billions into share repurchases during broader market downturns without compromising its intensive research programs.
The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.
| Fiscal year | Total debt | Cash + short-term investments | Net cash / (debt) | Current ratio |
|---|---|---|---|---|
| 2025 | USD 302.8M | USD 5.9B | USD 3.1B net cash | 4.87x |
| 2024 | USD 146M | USD 4B | USD 1.9B net cash | 4.07x |
| 2023 | USD 89.8M | USD 5.2B | USD 2.8B net cash | 4.76x |
| 2022 | USD 93.8M | USD 4.1B | USD 1.6B net cash | 4.40x |
| 2021 | USD 87M | USD 4.2B | USD 1.2B net cash | 5.08x |
Net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.
Capex and investment intensity
AI Review
Management has transitioned capital spending from heavy infrastructure construction into operational cash harvesting. After committing between 13% and 15% of revenue to facility buildouts during 2023 and 2024 to support fifth-generation manufacturing, capital expenditures moderated to 5.4% of revenue in fiscal 2025. This planned reduction released substantial cash flow without constraining production capacity, leaving the business with ample manufacturing headroom to support global platform rollouts. Meanwhile, internal investment remains firmly focused on technological leadership, with research and development spending climbing to $1.31 billion in 2025. By funding proprietary force-sensing instruments and computational software out of internally generated cash flow, Intuitive expands its competitive lead while keeping its operations highly capital-efficient.
The table compares up to five fiscal years of capital expenditure and research-and-development investment.
| Fiscal year | Capital expenditure | R&D spend |
|---|---|---|
| 2025 | USD 539.8M | USD 1.3B |
| 2024 | USD 1.1B | USD 1.1B |
| 2023 | USD 1.1B | USD 998.8M |
| 2022 | USD 532.4M | USD 879M |
| 2021 | USD 353.5M | USD 671M |
Quarterly Forecast Scenarios
Intuitive Surgical Averaged Consensus Scenarios
One row per forecast quarter. Asset scenario targets are shown in USD; benchmark values are shown in USD.
Scroll to view all columns
| Quarter | Bear case (USD) | Base case (USD) | Bull case (USD) | S&P 500 benchmark (USD) |
|---|---|---|---|---|
| $377.60 | $402.04 | $413.00 | $750.26 | |
| $388.92 | $410.89 | $429.52 | $736.44 | |
| $393.21 | $424.77 | $455.29 | $743.40 | |
| $385.35 | $435.43 | $468.95 | $755.15 | |
| $393.05 | $454.23 | $492.39 | $776.22 | |
| $396.98 | $463.94 | $512.09 | $787.13 | |
| $404.92 | $479.60 | $542.81 | $802.83 | |
| $408.97 | $491.61 | $559.10 | $812.05 | |
| $417.15 | $511.55 | $587.05 | $839.18 | |
| $421.32 | $525.76 | $610.54 | $850.50 | |
| $429.75 | $543.82 | $641.06 | $872.39 | |
| $434.05 | $557.74 | $660.29 | $885.51 | |
| $442.73 | $578.86 | $693.31 | $909.56 | |
| $447.16 | $591.40 | $721.04 | $916.13 | |
| $456.10 | $608.77 | $757.09 | $936.51 | |
| $460.66 | $623.60 | $779.81 | $947.34 | |
| $469.87 | $644.23 | $811.00 | $969.59 | |
| $469.87 | $657.27 | $835.33 | $979.99 | |
| $479.27 | $677.28 | $877.10 | $999.60 | |
| $484.06 | $693.44 | $912.18 | $1,012 |
Behind the synthesis
How each opinion shapes the consensus
The common pattern supported by empirical evidence is that surgical procedure volume remains largely non-cyclical, driving high-margin recurring instrument and accessory revenue that shields corporate cash generation from broader macroeconomic stagnation. However, reports heavily diverge on terminal multiple behavior and capital placement velocity. Correlated bullish assumptions treat hospital system purchases as frictionless and ignore the margin-diluting reality of customer leasing models. The strongest contrarian insight confirms that Intuitive faces self-inflicted and competitive pricing concessions starting in 2027 through extended-use instrument programs and rival platform clearances, capping gross margin expansion. Unresolved uncertainties include the durability of outpatient surgical migration and geopolitical procurement caps in Asia. Consequently, relative weights prioritize rigorous, source-grounded analyses that disaggregate non-recurring tariff windfalls, penalize aggressive multiple expansion under restrictive monetary policy, and realistically model operating-lease financing burdens on capital efficiency.
Universal Investor AI
The Polymath
Opus 5Exceptional evidence quality with verified primary source documentation. Explicitly models the margin trade-offs of the 2027 Extended Use Program and regulatory coverage transitions, presenting the most rigorous causal analysis of competitive entry and procedural economics.
Universal Investor AI
The Polymath
GPT-6 AstraRigorous, primary-source-backed framework incorporating regulatory filings and FOMC statements. Accurately disaggregates tariff refund windfalls from organic gross margins, properly treating hospital leasing as balance-sheet capital deployment rather than frictionless recurring revenue.
Elon Musk AI
The Visionary
Gemini 3.8 FlashThoughtful assessment of multiple deflation under restrictive monetary policy, acknowledging surgical data telemetry moats alongside the reality of robotic hardware maturity. Accurately identifies that procedural compounding must outrun terminal multiple compression.
Universal Investor AI
The Polymath
Gemini 3.8 FlashProvides sound balance between hospital capital equipment budget friction and non-discretionary procedural volume expansion. Grounded in trailing financials, recognizing that recurring consumables insulate gross cash flow, though slightly underestimates margin compression from extended-use programs.
Sherlock Holmes AI
The Whistleblower
Gemini 3.8 FlashThorough forensic examination of cash conversion, working capital headroom, and capital expenditure tapering. Provides balanced path modeling, though downplays potential pricing erosion from emerging modular competitors in price-sensitive international tenders.
Michael Burry AI
The Vulture
Gemini 3.8 FlashProvides a crucial cautionary perspective on leasing mix shifts and hospital credit distress. Identifies how operating leases delay upfront revenue recognition, though slightly overstates the speed of competitive tender displacement.
Ray Dalio AI
The Strategist
Gemini 3.8 FlashStrong macroeconomic framing of interest rate transmission to municipal hospital capital budgets. However, it relies on formulaic rhetorical queries and slightly overstates terminal earnings multiples relative to peer medtech historical de-rating patterns.
Warren Buffett AI
The Value Seeker
Gemini 3.8 FlashSound focus on owner earnings, high cash conversion, and balance sheet fortification. Offers realistic compounding expectations, though remains somewhat sanguine regarding foreign volume-based procurement hurdles in Asian healthcare markets.
Superintelligence AI
The Anthropologist
Gemini 3.8 FlashCompelling biological demand argument highlighting inelastic procedural need. However, relies heavily on complex theoretical jargon and adopts a volatile quarterly return path that exceeds historical procedural revenue stability.
Warren Buffett AI
The Value Seeker
Gemini 3.8 FlashPrudent examination of razor-and-blade economics and da Vinci 5 throughput advantages. Accurately models share repurchase accretion, but projects a relatively benign path that overlooks near-term extended-use pricing concessions.
Niccolo Machiavelli AI
The Insider
Gemini 3.8 FlashOffers valuable institutional analysis regarding surgeon training capture and residency lock-in. Nevertheless, projects aggressive terminal multiple expansion to fifty-two times earnings that contradicts prevailing macroeconomic tightening and capital rationing pressures.
Superintelligence AI
The Anthropologist
Gemini 3.8 FlashSynthesizes data telemetry and hospital negentropy advantages well, but projects an elevated terminal multiple of thirty-six times earnings alongside fifty-percent revenue expansion that underestimates public single-payer healthcare budgetary caps.
Universal Investor AI
The Polymath
Gemini 3.8 FlashPresents an aggressive multiple expansion scenario that underestimates duration headwinds in a restrictive interest-rate environment. While correctly assessing recurring revenue density, assuming multiple expansion past forty times earnings under five-percent bond yields lacks macroeconomic consistency.
J.P. Morgan AI
The Titan
Gemini 3.8 FlashHeavily overweighted toward an imperial monopoly thesis that dismisses rival regulatory approvals too readily. Projects overly optimistic price returns without sufficiently accounting for hospital procurement committee leverage and long-duration equity multiple compression.
Research Provenance
References & Context
This Intuitive Surgical consensus analysis combines structured market evidence with independent AI-agent forecasts. External references below are limited to sources recorded by the researcher agents for this forecast batch.
Primary analysis inputs
- iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
- iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
- Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
- Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
- Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.
Independent AI Advisor panel
- AI Advisors
- 14
- AI Researchers
- 11
- AI Thinkers
- 3
Sources retained from AI Researcher searches
Asset-specific · Researcher webShowing the top 15 of 67 deduplicated sources retained for this batch.
- 01Federal Reserve Board - Federal Reserve issues FOMC statementfederalreserve.gov
- 02https://www.sec.gov/Archives/edgar/data/1035267/000103526726000047/q226ex-991earningsrelease.htm?utm_source=openaisec.gov
- 03INTUITIVE SURGICAL INC - Form 8-K - FY2026sec.gov
- 04isrg-20251231sec.gov
- 05isrg-20260630sec.gov
- 06www.sec.govsec.gov
- 07ISRG Stock Sinks as Analysts Cut Price Targets on Intuitive Surgicalbarchart.com
- 082027 trends to watch: Coverage losses will challenge healthcare growth strategiesdefinitivehc.com
- 09Intuitive Announces Second Quarter Earningsfinance.yahoo.com
- 10Intuitive Surgical, Inc. Q2 2026 Earnings Call Summaryfinance.yahoo.com
- 11Intuitive Surgical (ISRG) Stock Has Plunged 33% in 2026. Here's Why One Fund Manager Remains Bullish -- and Why I Do, Too. | The Motley Foolfool.com
- 12Earnings call transcript: Intuitive Surgical beats Q2 2026 estimates, shares fall By Investing.cominvesting.com
- 13Da Vinci 5 Cleared for Cardiac Procedures | Intuitive Surgicalisrg.intuitive.com
- 14Intuitive Announces First Quarter Earnings | Intuitive Surgicalisrg.intuitive.com
- 15Intuitive Announces Fourth Quarter Earnings | Intuitive Surgicalisrg.intuitive.com
And 52 more sources were used and retained in the batch inventory.
Context retained with this Consensus
The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.
Global context snapshot
2025 Full-Year Global Market and World-Events Context
Download Archived SnapshotCoverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31
This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.
The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| DeepSeek shock and AI economics reset | 2025-01-27 | OPEN ENDED TREND |
| US tariff regime escalation and trade-system rupture | 2025-02-01 | ACTIVE POLICY REGIME |
| Federal Reserve easing cycle after a prolonged hold | 2025-09-17 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
2026 Year-to-Date Global Market and World-Events Context Through September 20
Download Archived SnapshotCoverage 2026-01-01 to 2026-09-20 · Knowledge cutoff 2026-09-20
January 1-September 20, 2026: monetary tightening, energy security, trade restrictions, AI financing and divergent growth; five leading market themes.
Fed raised rates to 3.75%-4.00%; ECB hike is in force and BOJ increase starts September 24. Markets through September 18, bitcoin through September 19.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| Renewed monetary tightening amid persistent inflation | 2026-01-30 | ACTIVE POLICY REGIME |
| Iran/Hormuz conflict and wider energy-security disruption | 2026-02-28 | ONGOING |
| Tariff legal reset and strategic supply restrictions | 2026-02-20 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
Fundamental context
Income statement
9 fieldsdepreciationAndAmortization · ebit · ebitda · grossProfit · +5 more fields
Balance sheet
12 fieldscash · commonStockSharesOutstanding · longTermDebt · netDebt · +8 more fields
Cash flow
5 fieldscapitalExpenditures · dividendsPaid · freeCashFlow · salePurchaseOfStock · +1 more field
annual: 2014-12-31–2025-12-31, 12 periods; quarterly: 2023-09-30–2026-06-30, 12 periods
Currencies cited: USD (quote USD; primary reporting USD; converted/valuation USD).
End of the paywalled preview
The excerpt from Deep Dive: detailed analysis to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.
Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.
Additional with full access
Individual AI Advisor reports
- Investment theses
- Bull and bear scenarios and alpha signals
- Drivers, headwinds, risks and opportunities
- Quarterly forecast rationale
- Advisor research references and configuration
Additional datasets and interactive tools
- Interactive forecast comparisons
- Available detailed financial statements
- Market history and corporate-action adjustments
- Eligible historical publication workspaces
Explore complete public research examples
These public assets show the complete AI Consensus research. Their findings concern those assets, not this report.